Platelet-derived circulating soluble P-selectin is sufficient to induce hematopoietic stem cell mobilization.


Journal

Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581

Informations de publication

Date de publication:
20 Oct 2023
Historique:
received: 25 11 2022
accepted: 09 10 2023
medline: 2 11 2023
pubmed: 21 10 2023
entrez: 20 10 2023
Statut: epublish

Résumé

Granulocyte colony-stimulating factor (G-CSF)-mediated mobilization of hematopoietic stem cells (HSCs) is a well-established method to prepare HSCs for transplantation nowadays. A sufficient number of HSCs is critical for successful HSC transplantation. However, approximately 2-6% of healthy stem cell donors are G-CSF-poor mobilizers for unknown reasons; thus increasing the uncertainties of HSC transplantation. The mechanism underlining G-CSF-mediated HSC mobilization remains elusive, so detailed mechanisms and an enhanced HSC mobilization strategy are urgently needed. Evidence suggests that P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) are one of the cell-cell adhesion ligand-receptor pairs for HSCs to keep contacting bone marrow (BM) stromal cells before being mobilized into circulation. This study hypothesized that blockage of PSGL-1 and P-selectin may disrupt HSC-stromal cell interaction and facilitate HSC mobilization. The plasma levels of soluble P-selectin (sP-sel) before and after G-CSF administration in humans and male C57BL/6J mice were analyzed using enzyme-linked immunosorbent assay. Male mice with P-selectin deficiency (Selp A significant increase in plasma sP-sel levels was observed in humans and mice following G-CSF administration. Treatments of G-CSF induced a decrease in the level of HSC mobilization in Selp sP-sel was identified as a novel endogenous HSC-mobilizing agent. sP-sel injections achieved a relatively faster and more convenient regimen to mobilize HSCs in mice than G-CSF. These findings may serve as a reference for developing and optimizing human HSC mobilization in the future.

Sections du résumé

BACKGROUND BACKGROUND
Granulocyte colony-stimulating factor (G-CSF)-mediated mobilization of hematopoietic stem cells (HSCs) is a well-established method to prepare HSCs for transplantation nowadays. A sufficient number of HSCs is critical for successful HSC transplantation. However, approximately 2-6% of healthy stem cell donors are G-CSF-poor mobilizers for unknown reasons; thus increasing the uncertainties of HSC transplantation. The mechanism underlining G-CSF-mediated HSC mobilization remains elusive, so detailed mechanisms and an enhanced HSC mobilization strategy are urgently needed. Evidence suggests that P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) are one of the cell-cell adhesion ligand-receptor pairs for HSCs to keep contacting bone marrow (BM) stromal cells before being mobilized into circulation. This study hypothesized that blockage of PSGL-1 and P-selectin may disrupt HSC-stromal cell interaction and facilitate HSC mobilization.
METHODS METHODS
The plasma levels of soluble P-selectin (sP-sel) before and after G-CSF administration in humans and male C57BL/6J mice were analyzed using enzyme-linked immunosorbent assay. Male mice with P-selectin deficiency (Selp
RESULTS RESULTS
A significant increase in plasma sP-sel levels was observed in humans and mice following G-CSF administration. Treatments of G-CSF induced a decrease in the level of HSC mobilization in Selp
CONCLUSIONS CONCLUSIONS
sP-sel was identified as a novel endogenous HSC-mobilizing agent. sP-sel injections achieved a relatively faster and more convenient regimen to mobilize HSCs in mice than G-CSF. These findings may serve as a reference for developing and optimizing human HSC mobilization in the future.

Identifiants

pubmed: 37864264
doi: 10.1186/s13287-023-03527-w
pii: 10.1186/s13287-023-03527-w
pmc: PMC10589967
doi:

Substances chimiques

P-Selectin 0
Granulocyte Colony-Stimulating Factor 143011-72-7
Recombinant Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

300

Subventions

Organisme : Ministry of Science and Technology, Taiwan
ID : MOST103-2321-B-320-001
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST105-2633-B-320-001
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST106-2633-B-320-001
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST108-2311-B-320-001
Organisme : Buddhist Tzu Chi Medical Foundation
ID : TCMMP104-06
Organisme : Buddhist Tzu Chi Medical Foundation
ID : TCMMP108-04
Organisme : Buddhist Tzu Chi Medical Foundation
ID : TCMMP111-01
Organisme : Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
ID : TCRD106-42
Organisme : Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
ID : TCRD108-55
Organisme : Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
ID : TCRD110-61
Organisme : Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
ID : TCRD111-082
Organisme : Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
ID : TCRD112-054
Organisme : Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
ID : TCAS-112-02

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

J Leukoc Biol. 2012 Jul;92(1):183-94
pubmed: 22566571
Exp Clin Cardiol. 2009 Fall;14(3):e76-9
pubmed: 20098572
N Engl J Med. 2017 Feb 2;376(5):429-439
pubmed: 27959701
Blood. 2014 Nov 6;124(19):2937-47
pubmed: 25202142
Biol Blood Marrow Transplant. 2009 Nov;15(11):1394-9
pubmed: 19822298
Handb Exp Pharmacol. 2007;(180):3-36
pubmed: 17554502
Naunyn Schmiedebergs Arch Pharmacol. 2014 Feb;387(2):109-18
pubmed: 24091681
Sci Rep. 2016 Oct 25;6:35868
pubmed: 27779216
Stem Cells. 2004;22(5):696-703
pubmed: 15342934
Biol Blood Marrow Transplant. 2013 Oct;19(10):1517-21
pubmed: 23891749
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14423-8
pubmed: 9826716
Stem Cells. 2007 Dec;25(12):3093-100
pubmed: 17717064
J Clin Exp Hematop. 2018 Sep 19;58(3):148-151
pubmed: 30089748
Blood Adv. 2019 Feb 12;3(3):406-418
pubmed: 30733301
J Clin Invest. 2017 Dec 1;127(12):4231-4234
pubmed: 29130939
N Engl J Med. 1988 Jun 2;318(22):1414-22
pubmed: 2452983
Bone Marrow Transplant. 1997 Feb;19(4):303-10
pubmed: 9051238
Transfusion. 2015 Dec;55(12):2855-63
pubmed: 26183707
Cell. 2002 May 31;109(5):625-37
pubmed: 12062105
Exp Hematol. 2005 Feb;33(2):232-42
pubmed: 15676218
J Clin Invest. 2003 Jan;111(2):187-96
pubmed: 12531874
Am J Hematol. 2012 May;87(5):536-9
pubmed: 22488107
Mol Ther. 2014 Sep;22(9):1580-92
pubmed: 24962162
Stem Cell Rev Rep. 2019 Jun;15(3):391-403
pubmed: 31089880
Blood. 1996 Oct 15;88(8):2819-25
pubmed: 8874177
Br J Haematol. 1998 Jan;100(1):66-9
pubmed: 9450793
Expert Opin Ther Targets. 2007 Nov;11(11):1473-91
pubmed: 18028011
Leukemia. 2010 Oct;24(10):1667-75
pubmed: 20703253
Int Immunol. 2019 Aug 23;31(9):617-625
pubmed: 31049553
Blood. 2010 Dec 2;116(23):5002-9
pubmed: 20699442
Ann Transl Med. 2019 Sep;7(18):482
pubmed: 31700918
Rambam Maimonides Med J. 2014 Oct 29;5(4):e0028
pubmed: 25386344
J Am Coll Cardiol. 2013 May 21;61(20):2048-55
pubmed: 23500230
J Hematol Oncol. 2021 Jan 6;14(1):3
pubmed: 33402221
Transfusion. 2002 Mar;42(3):328-33
pubmed: 11961238
J Exp Med. 1992 Apr 1;175(4):1147-50
pubmed: 1372646
Am J Pathol. 1996 Jan;148(1):165-75
pubmed: 8546203
J Exp Med. 1998 Aug 3;188(3):465-74
pubmed: 9687524
Cell. 2008 Feb 22;132(4):631-44
pubmed: 18295580
Curr Stem Cell Rep. 2017;3(3):172-180
pubmed: 28845386
Blood Rev. 2007 Mar;21(2):99-111
pubmed: 16987572
Nature. 2021 Jan;589(7843):591-596
pubmed: 33361809
Biochem Biophys Res Commun. 2007 Apr 20;355(4):970-5
pubmed: 17335773
Trends Immunol. 2014 Jan;35(1):32-7
pubmed: 24210164
Biol Blood Marrow Transplant. 2008 Nov;14(11):1305-11
pubmed: 18940686
Cell Mol Life Sci. 2021 May;78(10):4639-4651
pubmed: 33787980
Immunol Lett. 2012 Jul 30;145(1-2):47-54
pubmed: 22698183
Blood. 2003 Oct 15;102(8):2728-30
pubmed: 12855591
J Exp Med. 2005 Apr 18;201(8):1307-18
pubmed: 15837815
Eye (Lond). 2015 Aug;29(8):1112-3
pubmed: 25907208
Blood Cells. 1978;4(1-2):7-25
pubmed: 747780
Immunity. 1999 Sep;11(3):369-78
pubmed: 10514015
Stem Cell Res. 2013 Nov;11(3):1013-21
pubmed: 23939266
Int J Mol Sci. 2022 Oct 07;23(19):
pubmed: 36233211
Biol Blood Marrow Transplant. 2012 May;18(5):763-72
pubmed: 22227589
PLoS One. 2014 Aug 29;9(8):e105642
pubmed: 25170927
Exp Hematol. 2003 Feb;31(2):109-17
pubmed: 12591275
Trends Mol Med. 2003 Jun;9(6):263-8
pubmed: 12829015
Microvasc Res. 2001 Nov;62(3):335-45
pubmed: 11678636
Cell Death Dis. 2017 Nov 16;8(11):e3172
pubmed: 29144506
Blood. 2012 Jan 19;119(3):707-16
pubmed: 22049516
Cell. 2018 Jan 11;172(1-2):191-204.e10
pubmed: 29224778
Leukemia. 2010 May;24(5):976-85
pubmed: 20357827
Virulence. 2017 Oct 3;8(7):1216-1228
pubmed: 28102766
Leukemia. 2015 Jun;29(6):1366-78
pubmed: 25578474
Chest. 2004 Jul;126(1):54-8
pubmed: 15249442
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Bone Marrow Transplant. 2013 Aug;48(8):1112-6
pubmed: 23474805
Blood Rev. 2021 May;47:100771
pubmed: 33213986
Blood. 1995 Nov 15;86(10):3961-9
pubmed: 7579367
Transfus Apher Sci. 2017 Jun;56(3):470-473
pubmed: 28647301
Stem Cell Reports. 2019 Nov 12;13(5):787-792
pubmed: 31607567
Ann N Y Acad Sci. 2020 Apr;1466(1):24-38
pubmed: 31006885
Crit Care. 2014 Feb 18;18(2):204
pubmed: 24602331
J Clin Invest. 2002 Aug;110(4):559-69
pubmed: 12189250
Blood. 2012 Apr 26;119(17):3962-5
pubmed: 22422821
Blood. 2017 Jul 13;130(2):101-102
pubmed: 28705855
Biomark Insights. 2017 Feb 07;12:1177271916684823
pubmed: 28469394
Transl Res. 2017 May;183:1-13
pubmed: 28034759
PLoS One. 2021 Aug 13;16(8):e0255606
pubmed: 34388149
Tzu Chi Med J. 2021 Oct 21;34(3):270-275
pubmed: 35912054
Blood. 2001 Sep 1;98(5):1289-97
pubmed: 11520773
J Clin Med. 2022 Jul 18;11(14):
pubmed: 35887932
Front Immunol. 2019 Apr 12;10:811
pubmed: 31057544
Stem Cell Res Ther. 2021 May 29;12(1):310
pubmed: 34051862
Int J Hematol. 2011 May;93(5):652-659
pubmed: 21509437
Int J Hematol. 2017 Feb;105(2):129-140
pubmed: 27943116
Br J Haematol. 2006 Sep;134(5):517-25
pubmed: 17018030
J Clin Invest. 2017 Dec 1;127(12):4527-4540
pubmed: 29130940
Vox Sang. 2022 Jan;117(1):6-16
pubmed: 34159611
Nat Commun. 2015 Apr 02;6:6416
pubmed: 25832730
J Pharmacol Pharmacother. 2013 Oct;4(4):303-6
pubmed: 24250214
Chang Gung Med J. 2005 Sep;28(9):613-20
pubmed: 16323552
J Infect Dis. 2002 May 15;185(10):1490-501
pubmed: 11992286
N Engl J Med. 1957 Sep 12;257(11):491-6
pubmed: 13464965
Blood. 2005 Sep 1;106(5):1867-74
pubmed: 15890685

Auteurs

Tso-Fu Wang (TF)

Department of Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Republic of China.
Department of Medicine, College of Medicine, Tzu Chi University, Hualien, Taiwan, Republic of China.
Buddhist Tzu Chi Stem Cells Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Republic of China.

Yu-Shan Liou (YS)

Department of Molecular Biology and Human Genetics, College of Medicine, Tzu Chi University, No. 701, Section 3, Zhong-Yang Road, Hualien, 97004, Taiwan, Republic of China.

Shang-Hsien Yang (SH)

Department of Medicine, College of Medicine, Tzu Chi University, Hualien, Taiwan, Republic of China.
Buddhist Tzu Chi Stem Cells Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Republic of China.
Department of Pediatric Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Republic of China.

Guan-Ling Lin (GL)

Department of Molecular Biology and Human Genetics, College of Medicine, Tzu Chi University, No. 701, Section 3, Zhong-Yang Road, Hualien, 97004, Taiwan, Republic of China.
Integration Center of Traditional Chinese and Modern Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Republic of China.

Ya-Wen Chiang (YW)

Department of Molecular Biology and Human Genetics, College of Medicine, Tzu Chi University, No. 701, Section 3, Zhong-Yang Road, Hualien, 97004, Taiwan, Republic of China.

Te-Sheng Lien (TS)

Department of Molecular Biology and Human Genetics, College of Medicine, Tzu Chi University, No. 701, Section 3, Zhong-Yang Road, Hualien, 97004, Taiwan, Republic of China.

Chi-Cheng Li (CC)

Department of Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Republic of China.
Center of Stem Cell and Precision Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Republic of China.

Jen-Hung Wang (JH)

Department of Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Republic of China.

Hsin-Hou Chang (HH)

Department of Molecular Biology and Human Genetics, College of Medicine, Tzu Chi University, No. 701, Section 3, Zhong-Yang Road, Hualien, 97004, Taiwan, Republic of China. hhchang@mail.tcu.edu.tw.

Der-Shan Sun (DS)

Department of Molecular Biology and Human Genetics, College of Medicine, Tzu Chi University, No. 701, Section 3, Zhong-Yang Road, Hualien, 97004, Taiwan, Republic of China. dssun@mail.tcu.edu.tw.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH